Core Viewpoint - Sino Medical achieved a significant stock price increase of 19.99% on August 18, reaching a price of 41.48 CNY per share, with a trading volume of 2.032 billion CNY and a turnover rate of 12.37%, resulting in a total market capitalization of 17.258 billion CNY [1] Company Overview - Sino Medical Technology Co., Ltd. is located in the Tianjin Economic-Technological Development Area and specializes in the research, production, and sales of high-end interventional medical devices [1] - The company’s main products include coronary drug-eluting stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents, with over 1.4 million units used globally, serving hundreds of thousands of patients [1] - Sino Medical holds 8 key technologies, has launched 19 products, and possesses over 200 global patents, while undertaking 7 national and provincial scientific research projects [1] - Clinical research results of its products have been published in 31 articles in core domestic and international journals [1] Financial Performance - For the period from January to March 2025, Sino Medical reported a revenue of 101 million CNY, representing a year-on-year growth of 10.75% [1] - The net profit attributable to shareholders was 2.9693 million CNY, showing a substantial year-on-year increase of 277.50% [1] - As of March 31, the number of shareholders was 11,000, with an average of 37,400 circulating shares per person [1]

8月13日，赛诺医疗盘中19.99%涨停，截至14:19，报30.13元/股，成交30.05亿元，换手率26.34%，总市 值125.36亿元。 资料显示，赛诺医疗科学技术股份有限公司位于天津开发区第四大街5号泰达生物医药研发大厦B区2 层，公司是一家专注于高端介入医疗器械研发、生产、销售的国际化公司，主营产品包括冠脉药物支 架、冠脉球囊、颅内快速交换球囊、颅内药物洗脱支架等，累计使用超过140万个，服务于全球数十万 患者。公司拥有8项关键技术，已上市产品19款，全球专利数200余件，承担国家级、省级科研项目7 项，产品临床研究结果已在国内国际核心期刊发表31篇。 截至3月31日，赛诺医疗股东户数1.1万，人均流通股3.74万股。 2025年1月-3月，赛诺医疗实现营业收入1.01亿元，同比增长10.75%；归属净利润296.93万元，同比增长 277.50%。 来源：金融界 ...

Core Viewpoint - The company, Sainuo Medical Technology Co., Ltd., is expected to achieve significant growth in its half-year performance for 2025, with notable increases in both revenue and net profit [1][3]. Financial Performance Summary - The company anticipates a revenue of 240 million yuan for the first half of 2025, representing an increase of 26.78 million yuan or 12.53% compared to 214 million yuan in the same period last year [3]. - The net profit attributable to shareholders is projected to be 13.84 million yuan, a substantial increase of 10.35 million yuan or 296.54% from 3.49 million yuan year-on-year [3]. - The net profit after deducting non-recurring gains and losses is expected to be 7.98 million yuan, an increase of 20.57 million yuan or 163.35% from a loss of 12.59 million yuan in the previous year [3]. Growth Drivers - The significant growth in revenue is primarily driven by the increased sales of two coronary stent products and coronary balloon products that entered the centralized procurement range [10]. - The neuro-interventional business has shown steady growth, further contributing to the overall performance [10]. - Although operating costs have increased slightly year-on-year, reductions in sales and R&D expenses have effectively lowered overall costs [10]. - Management expenses have increased year-on-year, but a significant decrease in investment income and asset impairment losses has also contributed to profit growth [10]. Company Overview - Sainuo Medical, established on September 21, 2007, focuses on the research, development, production, and sales of high-end interventional medical devices [5]. - The company is headquartered in Tianjin and has subsidiaries in various locations including Beijing, Suzhou, Hong Kong, the United States, Japan, the Netherlands, and France [5]. - The main business areas include interventional treatment for cardiovascular, cerebrovascular, and structural heart diseases, with key products such as drug-eluting stents and balloon dilation catheters [5][6]. - The company has established a comprehensive quality management system and has received ISO 13485:2016 certification [7].

证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 赛诺医疗科学技术股份有限公司 为保障赛诺医疗科学技术股份有限公司（以下简称"公司"）全体股东的合法权益，维护 股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大会如期、顺利召开，根据《中 华人民共和国公司法》 《赛诺医疗科学技术股份有限公司章程》 《赛诺医疗科学技术股份有限公 司股东大会议事规则》及中国证监会、上海证券交易所的有关规定，特制定本须知。 一、股东大会设会务组，由公司董事会秘书负责会议的程序安排和会务工作。 二、为保证股东大会的严肃性和正常秩序，切实维护与会股东及股东代理人的合法权益， 除出席会议的股东及股东代理人、公司董事、监事、高级管理人员、见证律师及董事会邀请的 人员外，公司有权依法拒绝其他人员进入会场。 三、出席现场会议的股东及股东代理人须在会议召开前半小时到达会议现场办理签到手续， 并请按规定出示证券账户卡、身份证明文件或营业执照/注册证书复印件（加盖公章）、授权委 托书以及参会回执等，上述登记材料均需要提供复印件一份，个人登记材料复印件须个人签字， 法定代表人证明文件复印件须公司盖章，经验证后领取会议资料 ...

正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 赛诺医疗科学技术股份有限公司 （股票代码：688108.SH）成立于2007年9月21日，是一家专注于高端介入 医疗器械研发、生产及销售的国际化公司。公司总部位于天津经济技术开发区，同时在北京、苏州、香港、美 国、日本、荷兰、法国等地设有子公司。公司于2019年10月30日在上海证券交易所科创板上市。 赛诺医疗的主营业务涵盖 心血管、脑血管及结构性心脏病 等介入治疗领域的高端医疗器械研发、生产和销 售。公司的主要产品包括： 2025年4月26日， 赛诺医疗 发布了2024年年报。 | 主要会计数据 | 2024年 | 2023年 | 本期比上年同期 | 2022年 | | --- | --- | --- | --- | --- | | | | | 增减(%) | | | 营业收入 | 458,739,271.36 | 343,257,735.55 | 33.64 | 192,854,227.69 | | 扣除与主营业务无关的业务收入和不具备商 业实质的收入后的营业收入 | 457,942,375.80 | 340,02 ...